Tools   Select Another Resource Report Type

http://clinicaltrials.gov/show/NCT00100659

Multi-center, randomized controlled trial that studied peginterferon therapy, with or without ribavirin, in children with chronic hepatitis C. Approximately 120 children were randomly assigned to receive peginterferon alfa-2a alone or peginterferon with ribavirin for 48 weeks. Samples of blood, genomic DNA, and liver tissue are stored in the NIDDKrepositories. A long-term follow up study of the clinical trial participants is underway.

Proper citation: Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (RRID:SCR_006787) Copy   

•   Source: SciCrunch Registry

https://biolincc.nhlbi.nih.gov/home/

Repository that serves to coordinate searches across data and biospecimen collections from participants in numerous clinical trials and epidemiologic studies and to provide an electronic means for requests for additional information and the submission of requests for collections. The collections, comprising data from more than 80 trials or studies and millions of biospecimens, are available to qualified investigators under specific terms and conditions consistent with the informed consents provided by the individual study participants. Some datasets are presented with studies and supporting materials to facilitate their use in reuse and teaching. Datasets support basic research, clinical studies, observational studies, and demonstrations. Researchers wishing to apply to submit biospecimen collections to the NHLBI Biorepository for sharing with qualified investigators may also use this website to initiate that process.

Proper citation: Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) (RRID:SCR_013142) Copy   

•   Source: SciCrunch Registry

http://www.komp.org/

Repository of mouse vectors, ES cells, mice, embryos, and sperm generated by NIH KOMP Mutagenesis Project. In addition, KOMP Repository offers services in support of KOMP products, including ES cell microinjection, vector cloning, post-insertional modification of cloned ES cells, cryopreservation, assisted reproduction techniques (IVF, ICSI) and mouse breeding, pathology services, phenotyping services, etc. KOMP Repository is final component of more than $50 million trans-NIH initiative to increase availability of genetically altered mice and related materials. The University of California, Davis (UC Davis) and Children''s Hospital Oakland Research Institute (CHORI) in Oakland, Calif., are collaborating to preserve, protect, and make available about 8,500 types of knockout mice and related products available to research community. Products are generated by two KOMP mutagenesis teams (CSD consortium and Regeneron Inc). All KOMP products generated by CSD consortium and Regeneron are available through KOMP Repository. Notice as of December 19, 2019: Materials from KOMP Repository have been deposited into MMRRC, including all mouse models and mouse embryonic stem cell lines. Eventually www.komp.org will be sunsetting, and IMSR will remove KOMP Repository listings, since they were double listed in MMRRC. MMRRC will contain the most accurate and up to date resource models.

Proper citation: Knockout Mouse Project Repository (RRID:SCR_007318) Copy   

•   Source: SciCrunch Registry

http://www.nia.nih.gov/research/dab/nia-mutant-mouse-aging-colony-handbook

THIS RESOURCE IS NO LONGER IN SERVICE, documented on September 09, 2013. Supply aged mutant and transgenic mice for NIH-supported research directly related to the biology of aging. The mice are raised by the NIA's contractor, Taconic Farms, in Specific Pathogen-Free (SPF) barrier facilities. The strains in the mutant mouse aging colony have been donated by the investigators who developed the models, and those investigators are still the legally recognized owners of the intellectual property. A Material Transfer Agreement (MTA) is required to purchase the mice (a one-time requirement per strain). There are restrictions to the use of this colony as described in the MTA. These restrictions include a prohibition against breeding the mice purchased from the NIA Mutant Mouse Aging Colony, agreement that the mice will not be used for commercial purposes, and agreement that the mice and all derivatives will not be transferred to third parties. The restrictions are further spelled out in the MTA. Animals are sold by age, not weight, and ages are stated in 1 month intervals only; all animals born within a calendar month are considered to be the same age, so date of birth (DOB) is given as month/year. All mice are virgins. The mutant mouse aging colony is slated to end in September 2013. Old mice will be available until September 2013 but the availability of young mice will end earlier. Entries of different strains into the mutant mouse aging colony will end at different times, dependent on the lifespan and pattern of use of the strain. Mouse models include: * Snell Dwarf (3623) ??????????????? last entry will be the November 2011 DOB (date of birth) * Ames Dwarf (324) ??????????????? last entry will be the October 2012 DOB * A53T ???????????????????????-synuclein Transgenic (322) ??????????????? last entry will be the December 2012 DOB * GFP Transgenic (317) ??????????????? last entry will be the January 2013 DOB

Proper citation: NIA Mutant Mouse Aging Colony Handbook (RRID:SCR_007328) Copy   

•   Source: SciCrunch Registry

http://compmed.ouhsc.edu/brr.html

Center that conducts multidisciplinary studies on captive baboons and provides a resource of laboratory-born and laboratory-reared baboons for NIH-sponsored research programs.

Proper citation: Baboon Research Resouces (RRID:SCR_008333) Copy   

•   Source: SciCrunch Registry

http://www.mouse-genome.bcm.tmc.edu/ENU/MutagenesisProj.asp

THIS RESOURCE IS NO LONGER IN SERVICE. For updated mutant information, please visit MMRRC or The Jackson Laboratory. Produces, characterizes, and distributes mutant mouse strains with defects in embryonic and postembryonic development. The goal of the ENU Mutagenesis project III is to determine the function of genes on mouse Chromosome 11 by saturating the chromosome with recessive mutations. The distal 40 cM of mouse Chr 11 exhibits linkage conservation with human Chromosome 17. We are using the chemical N-ethyl-N-nitrosourea (ENU) to saturate wild type chromosomes with point mutations. By determining the function of genes on a mouse chromosome, we can extrapolate to predict function on a human chromosome. We expect many of the new mutants to represent models of human diseases such as birth defects, patterning defects, growth and endocrine defects, neurological anomalies, and blood defects. Because many of the mutations we expect to isolate may be lethal or detrimental to the mice, we are using a unique approach to isolate mutations. This approach uses a balancer chromosome that is homozygous lethal and carries a dominant coat color marker to suppress recombination over a reasonable interval.

Proper citation: Mouse Mutagenesis Center for Developmental Defects (RRID:SCR_007321) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/36

Data set and biosepecimens of a multi-center clinical trial to determine if treatment with beta-cell antigens can delay the onset of Type 1 Diabetes Mellitus (Type 1 DM) in non-diabetic relatives of persons with Type 1 DM. Insulin is a well characterized antigen specifically produced by beta-cells, and it was used for this purpose in the initial DPT-1 studies. The protocol for high risk subjects uses daily subcutaneous insulin injections and an annual course of intravenous insulin treatment, while the protocol for intermediate risk subjects uses daily doses of insulin administered orally. Neither injected nor oral insulin at the doses used were observed to delay or prevent diabetes, although further studies are needed to test whether oral insulin can delay diabetes in people in the intermediate risk group with high titers of insulin autoantibodies.

Proper citation: Diabetes Prevention Type 1 (RRID:SCR_001467) Copy   

•   Source: SciCrunch Registry

https://www.clinicaltrials.gov/study/NCT00360646

Prospective and retrospective registry of well-characterized cases of drug-induced liver disease. The goals of Network include the development of standardized procedures to identify and fully characterize bona fide cases of drug- and complementary and alternative medicines (CAM)-induced liver injury, and to conduct controlled, clinical studies that will include extensive collection of data, serum, DNA, and tissue specimens. Cases of liver injury due to herbal medications are also included. The network will also develop terminology and standardized definitions for DILI, and to develop causality assessment instruments that are sensitive, specific, and reproducible. DILIN is funded by a cooperative agreement and includes five clinical centers and a central data coordinating center. The research goals of DILIN are to: * Create a registry of carefully documented DILI cases * Identify clinical, immunological, and environmental risk factors for drug- and CAM-mediated hepatotoxicity * Create a bank of biological specimens consisting of DNA, plasma, and immortalized lymphocytes to facilitate detailed genetic analyses * Characterize the natural history of drug- and CAM-induced DILI for at least six months following enrollment * Develop the capability to recontact these individuals over an extended period of time so that additional studies exploring DILI mechanisms can be performed Two studies are being initiated by the network. In the Retrospective Study, the implicated drugs are restricted to isoniazid, phenytoin, combination clavulanic acid/amoxicillin, and valproic acid (Depakote), Nitrofurantoin, Trimethoprim-sulfamethoxazole, Minocycline, and Quinolone antibiotics. These drugs were chosen because they are frequently administered to patients not receiving other hepatotoxic drugs, making it easier to establish causality. Patients must be alive, and the date of onset of the DILI episode must be on or after January 1, 1994. In the Prospective Study, all incident cases of drug- and CAM-induced liver injury are being considered. Initial presentation to a healthcare professional must be within the previous six months. A detailed medication history of the implicated DILI drug together with all prescription, OTC, and herbal medications is being recorded. Liver and serological tests are being performed to characterize the injury and to exclude competing causes of liver injury. A blood sample is also being drawn for plasma storage and DNA isolation. These cases will be followed longitudinally to characterize the long-term effects of the DILI episode. For both studies, documented, clinically significant DILI must be recorded in the patient's medical charts so that a causal determination can be made. Patients will be excluded if they are unwilling or unable to provide a blood sample or participate in the genetics component. Children under two years of age at the time of enrollment are excluded due to blood-volume requirements. If you have patients who are eligible to participate in either study, please contact one the DILIN clinical sites. As a general policy, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigator-initiated research project applications for ancillary studies to ongoing, large-scale clinical trials, epidemiological studies, and disease databases supported by the Institute. These studies are focused on a wide range of diseases and conditions including diabetes, obesity, acute and chronic liver disease, chronic kidney disease, and benign prostatic hyperplasia, among others.

Proper citation: Drug-Induced Liver Injury Network (RRID:SCR_001524) Copy   

•   Source: SciCrunch Registry

http://www.nbrc.nite.go.jp/e/index.html

Collection of microbial resources and perform taxonomic characterization of individual microorganisms such as bacteria including actinomycetes and archaea, yeasts, fungi, algaes, bacteriophages and DNA resources for academic research and industrial applications. NBRC is a member of WFCC, OECD Global BRC Network, ACM and JSCC. They are certified by quality management system ISO 9001. To provide attractive biological resources with useful information attached, they actively collect potentially useful biological resources (microorganisms and cloned genes) and distributes them to promote basic research as well as industrial applications. At the Biological Resource Center, they explore, isolate and identify microorganisms from various natural environments and at the same time accept scientifically and industrially useful microorganisms from researchers in academic and industrial sectors. The microbial DNA library constructed at the Biotechnology Development Center is also part of their collection. To improve and expand the collection, new methodologies for the isolation, identification and preservation of microorganisms and DNA will be investigated and developed so as to provide biological resources of higher quality. Their resources serve, for example, as the standard for determining antimicrobial activity, in aseptic tests as well as for the production of pharmaceutical substances and will be constantly reinforced for wider distribution to researchers in academia and industries. Please refer to the catalog shown at the NBRC website for details.

Proper citation: NBRC (RRID:SCR_002660) Copy   

•   Source: SciCrunch Registry

http://cancergenome.nih.gov/

Project exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).

Proper citation: The Cancer Genome Atlas (RRID:SCR_003193) Copy   

•   Source: SciCrunch Registry

http://www.ebisc.org/

Consortium to address the increasing demand by researchers for quality-controlled, disease-relevant research grade induced Pluripotent Stem Cell (iPSC) lines, data and cell services by demonstrating an operational banking and distribution service of iPSC lines after 3 years and establishing subsequently for Europe a centralized, not-for-profit bank providing all qualified users with access to scalable, cost-efficient and customized products. The main facility will be at the Babraham Research Campus (Cambridge, UK) and will undertake cell expansion, QC and characterization. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) will coordinate cell line distribution. The Fraunhofer IBMT (Saarbr��cken, Germany) will provide comprehensive operational back up. In a phased business strategy EBiSC will hot-start distribution of lines contributed by iPSC Centres in 2014, lines collected based on specified user demand, will reach full scale operations in 2016, and with extended funding will become self-sustaining as a not for profit banking operation by 2019. EBiSC will spearhead Europe in the international standardization of iPSC banking by forging collaborative links with similar endeavors in the USA and Asia. It will also provide training to encourage adoption and use of the bank. The project has up to one year after completion to disseminate intellectual property or data created by the project.

Proper citation: EBiSC (RRID:SCR_003856) Copy   

•   Source: SciCrunch Registry

http://www.acceleratedcure.org/impact/repository/nmo

Special collection of Neuromyelitis Optica (NMO) biological samples and data to foster scientific collaboration for NMO Spectrum Disease that will lead to the prevention, clinical treatment programs and a potential cure for Neuromyelitis Optica (NMO) Spectrum Disease. In this initiative, people with NMO can enroll into the repository at ACP''s collection sites located in leading neurology clinics across the US. Participants provide blood samples and information, which will in turn be used by qualified scientists whose research will contribute to the diagnosis, prevention, treatment, and/or cure of NMO. NMO subjects are primarily enrolled through the efforts of a study nurse employed by UTSW. Accelerated Cure Project (ACP), University of Texas Southwestern (UTSW), and Guthy-Jackson will work together to invite people with NMO to participate in the repository. Participants can enroll by visiting one of the ACP repository sites or by accepting an enrollment visit from the UTSW nurse.

Proper citation: Guthy-Jackson Repository for Neuromyelitis Optica (RRID:SCR_004183) Copy   

•   Source: SciCrunch Registry

http://fantom.gsc.riken.jp/4/

The FANTOM consortium is an international collaborative research project initiated and organized by the RIKEN Omics Science Center. In earlier FANTOM efforts we cloned and annotated 103,000 full-length cDNAs from mouse and distributed them to researchers throughout the world. FANTOM1-3 focused on identifying the transcribed components of mammalian cells. This work improved estimates of the total number of genes and their alternative transcript isoforms in both human and mouse, expanded gene families, and revealed that a large fraction of the transcriptome is non-coding. In addition, with the development of Cap Analysis of Gene Expression (CAGE) FANTOM3 could map a large fraction of transcription start sites and revise our models of promoter structure. This updated web resource provides the previous FANTOM results mapped to current genome builds and presents the results of FANTOM4. In FANTOM4 the focus has changed to understanding how these components work together in the context of a biological network. Using deepCAGE (deep sequencing with CAGE) we monitored the dynamics of transcription start site (TSS) usage during a time course of monocytic differentiation in the acute myeloid leukemia cell line THP-1. This allowed us to identify active promoters, monitor their relative expression and define relevant regions for carrying out transcription factor binding site predictions. Computational methods were then used to build a network model of gene expression in this leukemia and the transcription factors key to its regulation. This work gives the first picture of the wiring between genes involved in acute myeloid leukemia and provides a strategy for identifying key factors that determine cell fates. In addition to the network, FANTOM4 data was used in two additional analyses. The first identified a novel class of short RNAs associated with transcription start sites and the second focused on the role of repetitive element expression in the transcriptome. TOOLS *Genome Browser: graphical display of genomic features, such as promoters, exon structures, H3K9 acetylation, transcription factors positioning on the genome, coupled with gene and promoter activities. *EdgeExpressDB: regulatory interactions, such as transcriptional regulation, post-transcriptional silencing with miRNA, and PPI, coupled with gene and promoter activities. *SwissRegulon: FANTOM4 TF regulation is predicted using Motif Activity Response Analysis (MARA) developed by Erik van Nimwegen at Biozentrum. Follow the link to carry out MARA on your own dataset. *Custom Tracks on the UCSC Genome Browser: FANTOM4 tracks on the UCSC Genome Browser Database. *The RIKEN integrated database of mammals: Integration of FANTOM4 data with other mammalian resources, in particular, produced by RIKEN.

Proper citation: FANTOM DB (RRID:SCR_002678) Copy   

•   Source: SciCrunch Registry

http://www.wmt.com

An ISO 9001 certified designer, manufacturing and distributing orthopedic implants and instrumentation worldwide for over 50 years. Wright''s product offerings include large joint implants for the hip and knee; extremity implants for the shoulder, elbow, hand, wrist and foot; and both synthetic and tissue-based bone graft substitute materials. Since its inception, Wright has introduced a number of products that represent new standards in orthopedic technology. From new material technologies to advanced products and instrumentation, Wright is committed to finding solutions to the challenges that face today''s orthopedic professionals.

Proper citation: Wright Medical Technology, Inc. (RRID:SCR_004195) Copy   

•   Source: SciCrunch Registry

http://www.bcgsc.ca/project/pleiades-promoter-project

Project to generate human DNA promoters of less than 4 kb (MiniPromoters) to drive gene expression in defined brain regions of therapeutic interest for diseases such as Alzheimer, Parkinson, Huntington, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinocerebellar Ataxia, Depression, Autism, and Cancer. Project develops and shares tools like human MiniPromoters that drive region- and cell-specific gene expression in the mouse brain, expression constructs, mouse embryonic stem cell lines, and knock-in mice all of which carry brain-specific MiniPromoters. Project is daughter of Genome Canada Project, Atlas of Gene Expression in Mouse Development, within which mouse brain gene expression data have already been gathered. Project team has collaborated with International BioPharma Solutions Ltd., management and communications consulting company specializing in product development and commercialization advice. Project will explore challenging interface between science and journalism with focus on genomics and gene therapy.

Proper citation: Pleiades Promoter Project: Genomic Resources Advancing Therapies for Brain Disorders (RRID:SCR_003282) Copy   

•   Source: SciCrunch Registry

http://www.mesotissue.org/

A virtual biospecimen registry designed to support and facilitate basic science, clinical, and translational research that will advance understanding of mesothelioma pathophysiology with the goal of expediting the discovery of preventive measures, novel therapeutic interventions, and ultimately, cures for mesothelioma. The NMVB resource is designed to provide mesothelioma tissue samples with high-quality and well-characterized multimodal annotated data to researchers. The NMVB team strongly believes that progress in translational and clinical research - in cancer as well as other disease areas - depends on the ability of researchers to access high-quality tissue that is associated with meaningful annotation. MVB database version 3.0 has been released that provides researchers real-time access to demographic, epidemiologic, pathologic, genotype, and follow-up data associated with biospecimens at no cost. Researchers interested in utilizing NMVB samples for their research may submit an application. All researchers (academic or commercial, United States or foreign) may apply for NMVB tissue specimens. NMVB currently has 966 annotated cases and 1198 biospecimens including: * Paraffin Embedded Tissue * Fresh Frozen Tissue * Blood and DNA Samples The NMVB also has developed mesothelioma tissue microarrays (TMAs) with associated multimodal data annotation. Additional TMAs will be available shortly.

Proper citation: National Mesothelioma Virtual Bank (RRID:SCR_003438) Copy   

•   Source: SciCrunch Registry

http://pcpgm.partners.org/biorepository

Two biorepositories, operated by the Partners HealthCare Center for Personalized Genetic Medicine, to serve the research community at Partners HealthCare. The BioSample Services Facility (BSF) provides sample storage and processing services. The Partners Biorepository for Medical Discovery (PBMD) is an enterprise-wide repository of high-quality, consented samples available to foster genetic research and advance understanding of genetic causes of common, complex diseases. Services provided by these cores include assistance with the collection and processing of samples for research use, extraction of DNA and isolation of serum and or plasma with monitored cryogenic storage to provide stability and availability of the materials. After processing, and in conjunction with the BioSample Services Facility, the samples stored within the Biorepository for Medical Discovery may be arrayed for further processing via multiple molecular techniques such as - sequencing, genotyping, and expression profiling.

Proper citation: Partners HealthCare Biorepository (RRID:SCR_003559) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/the-imse-studies-imse-i-and-imse-ii

Immunomodulatory drugs in multiple sclerosis (IMSE) is a nation-wide pharmacoepidemiological and genetic study on persons treated with Tysabri. The study focuses on response to treatment and development of neutralizing antibodies, and to perform large-scale genetic studies. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 1293 (June 2010)

Proper citation: KI Biobank - IMSE (RRID:SCR_005899) Copy   

•   Source: SciCrunch Registry

http://www.ochsner.org/donate_volunteer/ochsner_blood_bank/

The primary blood supplier for Ochsner Medical Center, Ochsner Health Center - Kenner, Ochsner Health Center - West Bank, Ochsner Baptist Health Center, Ochsner St. Anne General Hospital and Lady of the Sea General Hospital in Cut Off. In addition, Ochsner Blood Bank participates in blood-resource sharing with other local community hospitals. Ochsner Blood Bank''s mission is to provide an adequate and safe blood supply for the hospitals and communities Ochsner serves. More than 45,000 blood components were transfused just last year. There''s also supporting information that indicates there will be a significant increase in transfusions for the current year. Blood replacement removes some of the costs of blood, but more importantly it provides patients with a safe and adequate blood supply. It''s likewise insurance that blood will be readily available should the need arise. If you happen to need blood during a hospital stay, please consider asking your family and friends to replace the blood that was transfused. Ochsner offers a blood replacement plan that takes care of everything. It even provides coverage for your family members, or other designated individuals, to receive the replacement units for up to one year should they need them.

Proper citation: Ochsner Blood Bank (RRID:SCR_004287) Copy   

•   Source: SciCrunch Registry

http://biomed.brown.edu/rhode-island-biobank/

Cryogenic facility for human tissue and fluid samples under management of Brown University Division of Biology and Medicine and supports biomedical research on Brown campus and across affiliated hospitals of Warren Alpert Medical School.

Proper citation: Brown University Rhode Island Biobank Core Facility (RRID:SCR_004289) Copy   

•   Source: SciCrunch Registry